PIA
PCRX icon

Piedmont Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Piedmont Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-693
Closed -$22K – 1923
2018
Q2 		$22K Buy
+693
New +$23.9K ﹤0.01% 1561

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Piedmont Investment Advisors's PCRX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Pacira BioSciences (PCRX) in Q3 2018, closing a stake of 693 shares — an estimated $22K sold.

Piedmont Investment Advisors first reported a position in PCRX in Q2 2018 and held it in 1 quarter. The position peaked at $22K in Q2 2018. 187 funds tracked by Wall St. Rank hold PCRX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Pacira BioSciences position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 693 Pacira BioSciences shares in Q3 2018, an estimated $22K.
  • Piedmont Investment Advisors first reported a position in Pacira BioSciences in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Pacira BioSciences position peaked at $22K in Q2 2018.
  • 187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.